Abiopharma

🔍 Trempont Dominique (Executive)

Company: ON24 INC. (ONTF)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Sold 276,389 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1
• Sold 20,000 shares of Stock Options (Right to buy) at $13.33 per share (Derivative)
  Date: 2026-04-01 | Code: D | Expires: 2030-12-11 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2
• Sold 12,131 shares of Stock Options (Right to buy) at $1.35 per share (Derivative)
  Date: 2026-04-01 | Code: D | Expires: 2028-12-21 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2
• Sold 21,000 shares of Stock Options (Right to buy) at $1.23 per share (Derivative)
  Date: 2026-04-01 | Code: D | Expires: 2030-01-16 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Pursuant to the Agreement and Plan of Merger, dated as of December 29, 2025 (the "Merger Agreement") among the Issuer, Cvent Atlanta, LLC ("Parent"), and Summit Sub Corp. ("Merger Sub"), on April 1, 2026, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving company and a wholly-owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each outstanding share of Issuer common stock was automatically canceled and converted into the right to receive cash in an amount equal to $8.10 per share, without interest, with similar treatment for outstanding RSUs.
• F2: At the effective time of the Merger, each outstanding option to purchase Issuer common stock was automatically canceled and converted into the right to receive cash in an amount equal to $8.10 less the exercise price per share of such option.